摘要:
Systems and methods for providing spectral measurements are described. In one embodiment, a spectral measuring device comprises at least one radiation source configured to provide N (N≧2) linearly independent illuxninant sources characterized by M (M≧N) wavelength channels in a predetermined wavelength range; a sensor unit including at least one sensor, configured to be in optical communication with the radiation sources and an object; a memory storing an illuminant characterization matrix including spectral characteristics of the N illuminant sources in the M wavelength channels; and a processor configured to provide spectral responses of the object in the M wavelength channels, based at least in part on the illuminant characterization matrix. The embodiments of the invention can be used to construct a new class of compact spectral measuring devices, such as handheld color measuring devices.
摘要:
Systems and methods for providing spectral measurements are described. In one embodiment, a spectral measuring device comprises at least one radiation source configured to provide N (N≧2) linearly independent illuxninant sources characterized by M (M≧N) wavelength channels in a predetermined wavelength range; a sensor unit including at least one sensor, configured to be in optical communication with the radiation sources and an object; a memory storing an illuminant characterization matrix including spectral characteristics of the N illuminant sources in the M wavelength channels; and a processor configured to provide spectral responses of the object in the M wavelength channels, based at least in part on the illuminant characterization matrix. The embodiments of the invention can be used to construct a new class of compact spectral measuring devices, such as handheld color measuring devices.
摘要:
Embodiments disclosed herein relate to reagent containers configured to allow for different liquid and solid reagents to be mixed in situ prior to the measurement.
摘要:
Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
摘要:
Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
摘要:
The present invention provides methods of using PROK2 and PROK1 antagonist, including monoclonal antibodies to treat inflammation, angiogenesis, and cancer.
摘要:
A method for treating psoriasis. An antagonist to IL-17Dβ9 (IL-17D) is administered to treat psoriasis. The antagonist can be an antibody that binds to IL-17Dβ9 or its receptor or a soluble receptor that binds to IL-17Dβ9 or a membrane-spanning protein-5 (MSP-5).
摘要:
Novel secreted and membrane bound tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate inflammation, tumor growth and metastasis, infection, immunity, and cellular maturation.
摘要:
Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
摘要:
Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.